Researchers discovered that TM4SF1 marks dysfunctional beta cells in the pancreas. The findings provide a potential target ...
A phase 1/2 study evaluating the safety and efficacy of autologous TAC T cells in subjects with claudin 18.2+ advanced solid tumors. This is an ASCO Meeting Abstract from the 2025 ASCO ...
CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- August 7, 2024: Angiex, a developer of Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapies for solid cancers, announced that the first ...
“These findings establish TM4SF1 as a robust and selective marker of senescent β-cells and support its potential as a target for β-cell-directed senotherapeutic strategies in T2DM.” Type 2 diabetes is ...
CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Angiex, a developer of Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapies for solid cancers, announced that the U.S. Food and Drug ...
Angiex, a developer of nuclear-delivered antibody-drug conjugate (ND-ADC) therapies for solid cancers, announced that the first patient has been dosed in the phase 1 clinical trial of AGX101, a novel ...
Kawasaki Gakuen has divulged pyrrole-imidazole polyamides acting as transmembrane 4 L6 family member 1 (TM4SF1) and TMEM132b expression inhibitors reported to be useful for the treatment of cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results